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ABSTRACT
Introduction. Hemodialysis patients 
experience major changes in lifestyle and suffer 
various physical and emotional symptoms, 
especially symptoms of depression and sexual 
dysfunction in more than half of patients. Sexual 
dysfunction in women is often not identified because 
of lack of attention, especially by the clinician. 
Symptoms of depression limit intimacy, and affect 
sexual arousal and orgasm.
Aim : the aim of the study was to determine 
the correlation between depressive symptoms and 
female sexual function index (FSFI) in women 
hemodialysis patients in the Hemodialysis Unit of 
Dr. Sardjito General Hospital Yogyakarta.
Methods. The method of this study was 
cross-sectional. Research was conducted at the 
Hemodialysis Unit by Dr. Sardjito General Hospital 
Yogyakarta from 10 April to 24 April 2012. 
Result. There were 42 female patients 
undergone routine hemodialysis who met the 
criteria. The median age was 49 years old and had 
undergone hemodialysis for a median duration of 40 
months. 
Conclusion. There was a negative 
correlation of depression symptoms and female 
sexual dysfunction with a moderate strength (r = -
0.421) and statistical significantly (P <0.05). Age 
and prolactin had a negative correlation with a 
moderate strength of FSFI score. HDL levels and 
menstrual status had a positive correlation with 
FSFI, with weak and strong correlation respectively.
Key Words: Female sexual function index, 
depression, hemodialysis
INTRODUCTION
Female hemodialysis patients suffer from 
various physical and emotional symptoms, mainly 
showing symptoms of depression, and impaired 
quality of life, including fatigue, pain, muscle 
cramps, insomnia, and sexual dysfunction in more 
than half of patients with chronic dialysis (Kader et 
al ., 2007). The incidence of sexual dysfunction is 
fairly high in patients with chronic renal failure 
(CRF)  The prevalence of men and women who 
received renal replacement therapy (dialysis or 
transplantation) is 60-75%, and sexual disorder is up 
to 90% (Levin et al., 2001).
Sexual arousal in women is strongly 
modulated by the thoughts and emotions, instigated 
by sexual stimulation. An emotional relationship 
with a partner and emotional well-being is the 
strongest predictor of sexual distress (Sadock and 
Sadock, 2004). Empirically, the symptoms of 
depression limit intimacy, and affect sexual arousal 
and orgasm. The value of high symptoms of 
depression symptoms frequently found in 
hemodialysis patients, and is associated with sexual 
dysfunction in previous studies (Peng et al., 2007).
Assessment of depression symptoms and 
sexual dysfunction has not been done on 
hemodialysis patients in the Hemodialysis Unit of 
Dr. Sardjito General Hospital, Yogyakarta, 
especially in female patients. In this study the 
researcher tried to determine the relationship 
between depressive symptoms of sexual 
dysfunction in women as measured by the Female 
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Depressive  Value
Figure 2. Scatter plot between depression and female sexual dysfunction
Correlation of depression symptoms with 
total FSFI values obtained using the Spearman test 
showed the significance value of 0.03 with negative 
correlation and the value of -0.421. The strength of 
this correlation was moderate and statistically 
significant.
These results are consistent with previous 
studies that the higher the BDI score was 
significantly associated with lower FSFI total with 
the â coefficient of -0.341 (p <0.001) (Peng et al., 
2005). Sexual dysfunction in women is 
independently associated with symptoms of 
depression on the CES-D scale. In non-sexual 
dysfunction 15.2 ± 10.0 compared with the CES-D 
at 21.8 ± 11.3 in sexual dysfunction (p <0.001) 
(Strippoli, 2012). Found a correlation -0.37 (p<0.01) 
between sexual function with symptoms of major 
depression in patients with chronic renal failure 
undergoing hemodialysis in Greece (Theofiliou, 
2012).
Table 2. Correlation between female sexual dysfunction with the duration 
of hemodialysis, age, HB, prolactin, dyslipidemia and menstrual status
Independent 
Variable 
Dependent Variable N  Coefficient  
(r)  
p  
Length of HD* female sexual dysfunction 42  0.048  0.762  
Age* female sexual dysfunction 42  -0.451  0.003  
HB Value* female sexual dysfunction 42  -0.019  0.903  
Prolactin* female sexual dysfunction 30  -0.490  0.025  
HDL* female sexual dysfunction 33  0.395  0.023  
*Spearman test
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The correlation between several factors that 
possibly influence the female sexual dysfunction in 
female hemodialysis patients was analyzed. The 
duration of hemodialysis and HB levels showed a 
weak correlation and was not statistically 
significant. HDL levels, age, prolactin levels and 
menstrual status showed moderate to strong 
correlations and were statistically significant.
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Age showed a correlative value of -0.451 (p 
= 0.003) to the FSFI score, this value means that the 
higher the age, the lower the total FSFI score with 
moderate strength and the correlation was 
statistically significant. These results were 
consistent with previous findings that the average 
age of sexual dysfunction in non-responders were 
44.6 ± 12.1 compared with respondents with sexual 
dysfunction, age 61.5 ± 14.3 (p <0.001) (Strippoli, 
2012).
DISCUSSION
Prolactin levels in this study had a 
correlation of -0.818 (p = 0.027) of the FSFI score, 
with the meaning that the higher levels of prolactin, 
the lower the total FSFI score. This result 
corresponds to previous research that a number of 
25 women with primary hiperprolactinemia 
compared with 16 controls obtained a median FSFI 
score was 23.4 (range 17.7 to 27.3) compared to 
healthy women had a median total FSFI score of 
31.10 (range 27, 55 to 32.88) (p <0.001) (Darwish et 
al., 2007).
Menstrual status has a strong correlation to 
total FSFI score with a value of r = 0.849 (p = 0.002), 
the more regular menstruation than the higher the 
total FSFI score. In the postmenopausal patients the 
possibility of various factors that contribute to 
sexual dysfunction, among others, the production of 
estrogen, estrogen receptor sensitivity and number 
of receptors, and the degree of stimulation of 
stimulation (Bhasinet Basson, 2011).
Dyslipidemia in previous studies was 
strongly associated with sexual dysfunction in 
women on dimensions of quality, desire, 
lubrication, orgasm, and clitoral sensation (Peng, et 
al., 2005). The dyslipidemia variable used in 
previous studies was hypertriglyceridemia, whereas 
the variables used in this study were HDL. In this 
research, showed the higher the HDL the better 
female sexual function with r 0.395 (p <0.023).
Renal anemia negatively affects the health 
of sex, the presence of chronic fatigue and weakness 
due to anemia symptoms contribute to decreased 
libido and the ability to have sex. Giving 
erythropoietin and correction of anemia were 
significantly associated with improved sexual 
ability (Levin, 2001). In this study a weak 
correlation between the levels of non-significant 
and HB with total FSFI scores was found.
CONCLUSION 
Symptoms of depression had a negative 
correlation with female sexual function with 
moderate strength. Further research is needed with a 
method to find the relationship between the two 
proportions to find the estimated risk of depression 
on sexual dysfunction in female hemodialysis 
patients. Adjustments for the confounding factors 
that affect female sexual dysfunction which are age, 
prolactin levels, dyslipidemia and menstrual status 
is required.
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INTRODUCTION 
Non-steroidal anti-inflammatory drugs 
(NSAIDs) are one of the most commonly prescribed 
1medication.  The gastrointestinal tract and kidneys 
are important targets of clinical events associated 
2with the use of NSAIDs.  Selective COX-2 
inhibitors have minimal gastrointestinal side effects. 
However, the newer NSAIDs also has nephrotoxic 
1effects remain as nonselective NSAIDs.  
The kidneys are the major organ for drug 
excretion, so that the renal arterioles and glomerular 
capillaries are especially vulnerable to the effects of 
3drugs.  The spectrum of NSAID-induced 
nephrotoxicity includes acute tubular necrosis, acute 
tubulointerstitial nephritis, glomerulonephritis, 
renal papillary necrosis, chronic renal failure, salt 
and water  retent ion,  hypertension,  and 
1hyperkalemia.  
Among the various clinical complications, 
the effects on the kidney are probably the most 
4common and severe due to the use of NSAIDs.  Fifty 
million US citizens report NSAIDs use, and it has 
been estimated that 500.000 – 2,5 million people 
will develop NSAID nephrotoxicity in the US 
5annually.  It has been reported that 37% of drug-
associated acute renal failure is associated with the 
use of NSAIDs, and NSAID-induced acute renal 
failure accounts for 7% of overall cases of acute 
4renal failure.  
This review discusses the NSAIDs, 
mechanisms and clinical manifestations of NSAID-
induced renal impairment and some NSAID options 
that can be used in patients with renal failure. 
NSAIDs 
NSAIDs have their origin in the extracts of 
salicylate-containing plants, in particular were 
known for their antipyretic, analgesic and anti-
6inflammatory properties.  NSAIDs exerts anti-
inflammatory, analgesic and anti-pyretic effects 
through the suppression of prostaglandin (PG), by 
inhibiting the enzyme cyclooxygenase (COX). Two 
isoforms of this enzyme COX-1 and COX-2 are 
known to exist. Nonselective NSAIDs inhibit both 
2COX-1 and COX-2.  Selective NSAIDs (COX-2 
selective inhibitors) inhibiting only the COX-2 
7isoform.  
Pharmacokinetics of NSAIDs 
Most NSAIDs are organic acids and are well 
absorbed in the gastrointestinal tract without 
substantial decreases in their bioavaibility with the 
highest concentration 1 to 4 hours. NSAIDs 
undergoes metabolism in the liver and are excreted 
through the kidneys. NSAIDs is largely bound to 
albumin in the blood (95% -99%) and have low 
volume of distribution. NSAIDs may across the 
blood brain barrier depending on lipid solubility. 
The half-life varies for different NSAIDs, but are 
generally divided into short (<6 hours) and long (>6 
hours). Mechanisms of action and side effects of 
NSAIDs for each patient varies depending on the 
type of NSAID used. This difference arises because 
of differences in the absorption, distribution and 
8metabolism in the human body.  
Physiological Role of Prostaglandins in the 
Kidney 
Prostaglandins were first described by 
Goldblatt as substances produced by the prostate 
gland and contained in the seminal fluid, with 
antihypertensive properties. Subsequently, it was 
shown that prostaglandins are produced by a large 
variety of cells in the human body. During the 
